Comparing the current results to its competitors, Theratechnologies Inc reported Revenue increase in the 4 quarter 2024 by 5.02 % year on year. The revenue growth was below Theratechnologies Inc 's competitors' average revenue growth of 8.91 %, achieved in the same quarter.
Theratechnologies Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 8.38 %
Theratechnologies Inc 's Comment on Competition and Industry Peers
The Company holds exclusive licensing and distribution agreements with TaiMed for Trogarzo® in Canada and the United States, and with Transfert Plus for the SORT1+ Technology™ platform. Trogarzo® competes with Fostemsavir and Lenacapavir, which target the same patient population but differ in administration methods. Additional agents such as dolutegravir and darunavir are also used in treatment regimens for heavily treatment-experienced patients with multidrug-resistant HIV-1. Olezarsen competes with other drugs developed for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG). Donidalorsen, currently under FDA review with a PDUFA date of August 21, 2025, competes with other prophylactic treatments for hereditary angioedema (HAE). The oncology segment is highly competitive, with numerous companies developing cancer treatments including antibody-drug conjugates; the Company may seek partners to advance its oncology programs. Government regulations in the United States affect the commercialization of EGRIFTA SV® and Trogarzo®.
April 11, 2025
In recent developments, Future Pak, LLC has taken significant steps towards acquiring Theratechnologies Inc. (NASDAQ: THTX) by submitting two formal acquisition proposals since January 2023. The latest proposal offers a cash consideration ranging from $3.51 to $4.50 per share, placing the total enterprise value of the acquisition at approximately $255 million. This venture reflects Future Pak s ambition to expand its portfolio in the biopharmaceutical sector. However, the context surrounding this acquisition proposal is telling of Theratechnologies current position in the market. In the fourth quarter of 2023, the company reported a stagnant year-on-year revenue growth rate of 0%. This performance is partic...
December 18, 2024
Biopharmaceutical Innovation and Digital Security: A Dual Frontiers Approach As the biopharmaceutical landscape continues to evolve, companies like Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) are at the forefront of innovation, driving forward their clinical and manufacturing capabilities. Recently, Theratechnologies announced a significant regulatory milestone by submitting a Prior Approval Supplement (PAS) to the United States Food and Drug Administration (FDA). This submission pertains to updates in the manufacturing environment of their critical product, EGRIFTA SV, a therapy recognized for its utility in managing HIV-associated lipodystrophy.The PAS is a regulatory document that details manufacturin...
April 8, 2024
Theratechnologies Showcases Versatility of SORT1+ Technology in Preclinical Data Presentation Theratechnologies, a biopharmaceutical company dedicated to the development of innovative therapies, recently presented preclinical data highlighting the versatility and flexibility of their SORT1+ Technology platform. The data were shared during a poster session at the 2024 annual meeting of the American Association for Cancer Research (AACR) in San Diego, California.The research conducted by Theratechnologies focused on their investigational camptothecin-peptide conjugates, which were found to be well tolerated and associated with significant tumor regression in xenograft models of colorectal cancer (CRC) and trip...
March 28, 2024
MONTREAL, March 28, 2024 - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies, is poised to make a significant impact in the field of cancer research with its advanced SORT1+ Technology platform. The company has announced its participation in the highly anticipated American Association for Cancer Research (AACR) Annual Meeting 2024, during which it will present two posters showcasing the potential of its platform.The SORT1+ Technology platform is designed to target and deliver therapeutic agents specifically to cancer cells, leading to improved efficacy and reduced toxicity compared to traditional treatment ap...
March 22, 2024
Leading the Charge in Cybersecurity: Embracing Outsourced Solutions to Navigate an Evolving Digital LandscapeNashville, Tenn., March 22, 2024 - In today s fast-paced and ever-evolving cyber landscape, organizations worldwide are grappling with a multitude of challenges. From the increasing demand for cybersecurity resources to the constant turnover of cybersecurity leadership and the emergence of complex compliance issues, the digital world presents a series of hurdles for businesses. However, in response to these challenges, a growing number of organizations are turning to experienced outsourcing solutions to effectively secure their digital frontiers.The digital revolution has vastly transformed the way bu...
March 21, 2024
Theratechnologies Expands Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide for Advanced Ovarian CancerMONTREAL, March 21, 2024 - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company specializing in innovative therapies, has recently announced its progress in the Phase 1 clinical trial of sudocetaxel zendusortide for patients with advanced ovarian cancer. The company has successfully reached a milestone and is now moving on to the next dose level in Part 3 of the trial.The Medical Review Committee (MRC) overseeing the study has determined that the dose level used in the first cohort of patients was safe, marking an important step in the development of this potential tre...
January 23, 2024
Theratechnologies Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapies, recently received an update from the U.S. Food and Drug Administration (FDA) concerning its supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin. The FDA has informed the Company that it is extending the review process beyond the initial Prescription Drug User Fee Act (PDUFA) goal date of January 22, 2024.Background:Theratechnologies sBLA for the F8 formulation of tesamorelin is aimed at addressing specific medical conditions and improving patient outcomes. Tesamorelin is a synthetic peptide that has been studied for its potential benefits in v...
Eqrx Inc is a pharmaceutical company that focuses on creating affordable and accessible medication. They employ an innovative business model that combines research and development with scientific expertise to develop generic alternatives to the high-priced drugs in the market. By bypassing the traditional pharmaceutical pricing system, Eqrx aims to make essential medications more affordable for patients and healthcare providers.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Theratechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Theratechnologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
